BridgeBio Oncology Therapeutics, Inc.
BBOT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001869105
In the last 90 days, BridgeBio Oncology Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 88 institutions reported holding it in 13F filings for Q3 2026, worth $246.7M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 19, 2026
- $149.3M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $184.86 in total
- 1
- 13F holdersQ3 2026, +24 vs. previous quarter
- 88
- 13F valueReported value at the end of Q3 2026
- $246.7M
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $11.3M
- No comparable prior period
- Net income, FY2025
- -$134.0M
- −1,863.9% year over year
- Free cash flow, FY2025
- -$114.5M
- No comparable prior period
- Revenue, Q3 FY2026
- $3.26M
- −5.3% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $134.0M (1181.7% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 3.47M
- Shares sold short
- Change
- −377.8K
- −9.8% vs. previous
- Days to cover
- 5.10
- At average daily volume
Superinvestors holding BBOT, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding BBOT at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by BridgeBio Oncology Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 17, 2026 (view filing)4:35 PM ET | Nov 13 | 4 days | Cobo MarcPrincipal Accounting Officer | SSale | −78 | $2.37 | −$184.86 | −0.6%13.7K after | 10b5-1 |
| Feb 13, 2024 (view filing) | Feb 13 | Same day | Chen BihuaCEO and Chairperson | PPurchaseClass A Ordinary Shares | +2.40M | $10.00 | +$24.0M | New position903.6K after | 3 lots |
Top 10 13F holders, Q3 2026
See all 88 holdersThe largest institutional positions in BridgeBio Oncology Therapeutics, Inc. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Cormorant Asset Management, LP | 17,878,594 | $73.3M | 4.92% | 00.0% | Unchanged |
| BlackRock, Inc. | 4,009,791 | $16.4M | 0.00% | +1,855,751+86.2% | Added |
| Omega Fund Management, LLC | 3,289,661 | $13.5M | 10.78% | 00.0% | Unchanged |
| Deerfield Management Company, L.P. (Series C) | 3,138,167 | $12.9M | 0.20% | −1,747,279−35.8% | Reduced |
| Alphabet Inc. | 2,823,126 | $11.6M | 0.01% | 00.0% | Unchanged |
| Citadel Advisors LLC | 2,697,077 | $11.1M | 0.01% | +79,250+3.0% | Added |
| Enavate Sciences GP, LLC | 2,626,946 | $10.8M | 3.85% | 00.0% | Unchanged |
| Regents of the University of California | 2,509,446 | $10.3M | 0.15% | +2,509,446 | New |
| Armistice Capital, LLC | 2,264,000 | $9.28M | 0.31% | +500,000+28.3% | Added |
| Novo Holdings A/S | 2,250,000 | $9.22M | 0.62% | 00.0% | Unchanged |
Holders of 5% or more of BBOT
See all 7 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of BridgeBio Oncology Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Helix Holdings II LLC | 13D/A | 31.59%7.39M shares | – | Feb 20, 20242 filings | Mar 4, 2025 | SEC |
| Helix Holdings II LLC | 13D/A | 22.60%17.9M shares | – | Aug 13, 20251 filing | Aug 13, 2025 | SEC |
| Chen Bihua | 13D/A | 22.32%17.9M shares | – | Jul 6, 20261 filing | Jul 6, 2026 | SEC |
| BridgeBio Pharma LLC | 13D | 17.50%13.9M shares | New | Aug 18, 20251 filing | Aug 18, 2025 | SEC |
| BlackRock Portfolio Management LLC | 13G | 7.90%1.50M shares | New | Apr 15, 20251 filing | Apr 15, 2025 | SEC |